Global Non-Cancerous Skin Diseases Therapeutics Market 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	176 Pages	TechNavio	January, 2024	INF18436669

Best Price Guarantee
Price	from $2,500
Length	176 Pages
Publisher	TechNavio
Published Date	January, 2024
SKU	INF18436669

Non-Tumorous Skin Diseases Therapeutics Market 2024-2028

The non-tumorous skin diseases therapeutics market is forecasted to grow by USD 25.22 bn during 2023-2028, accelerating at a CAGR of 9.88% during the forecast period. The report on the non-tumorous skin diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of skin diseases, strong pipeline landscape in non-cancerous skin diseases therapeutics, and growing demand for personalized non-cancerous skin diseases therapeutics.

Technavio's non-tumorous skin diseases therapeutics market is segmented as below:

By Therapy Area

Psoriasis
Eczema
Acne vulgaris
Others

By Route Of Administration

Injectable
Oral
Topical

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the increased focus on microbiome and skin barrier as one of the prime reasons driving the non-tumorous skin diseases therapeutics market growth during the next few years. Also, misdiagnosis of skin diseases and increasing healthcare expenditure will lead to sizable demand in the market.

The report on the non-tumorous skin diseases therapeutics market covers the following areas:

Non-tumorous skin diseases therapeutics market sizing
Non-tumorous skin diseases therapeutics market forecast
Non-tumorous skin diseases therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-tumorous skin diseases therapeutics market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Incyte Corp., LEO Pharma AS, Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., UCB SA, Viatris Inc., and XBiotech Inc.. Also, the non-tumorous skin diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Global Market Characteristics; Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape; Exhibit 05: Executive Summary - Chart on Market Segmentation by Therapy Area; Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibit 07: Executive Summary - Chart on Incremental Growth; Exhibit 08: Executive Summary - Data Table on Incremental Growth; Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 10: Parent market; Exhibit 11: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 12: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 13: Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion); Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion); Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Global non-cancerous skin diseases therapeutics market 2018 - 2022; Exhibit 18: Historic Market Size - Data Table on global non-cancerous skin diseases therapeutics market 2018 - 2022 ($ billion); 4.2 Therapy area Segment Analysis 2018 - 2022; Exhibit 19: Historic Market Size - Therapy area Segment 2018 - 2022 ($ billion); 4.3 Route of Administration Segment Analysis 2018 - 2022; Exhibit 20: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ billion); 4.4 Geography Segment Analysis 2018 - 2022; Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion); 4.5 Country Segment Analysis 2018 - 2022; Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis: 5.1 Five forces summary; Exhibit 23: Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Therapy Area: 6.1 Market segments; Exhibit 30: Chart on Therapy Area - Market share 2023-2028 (%); Exhibit 31: Data Table on Therapy Area - Market share 2023-2028 (%); 6.2 Comparison by Therapy Area; Exhibit 32: Chart on Comparison by Therapy Area; Exhibit 33: Data Table on Comparison by Therapy Area; 6.3 Psoriasis - Market size and forecast 2023-2028; Exhibit 34: Chart on Psoriasis - Market size and forecast 2023-2028 ($ billion); Exhibit 35: Data Table on Psoriasis - Market size and forecast 2023-2028 ($ billion); Exhibit 36: Chart on Psoriasis - Year-over-year growth 2023-2028 (%); Exhibit 37: Data Table on Psoriasis - Year-over-year growth 2023-2028 (%); 6.4 Eczema - Market size and forecast 2023-2028; Exhibit 38: Chart on Eczema - Market size and forecast 2023-2028 ($ billion); Exhibit 39: Data Table on Eczema - Market size and forecast 2023-2028 ($ billion); Exhibit 40: Chart on Eczema - Year-over-year growth 2023-2028 (%); Exhibit 41: Data Table on Eczema - Year-over-year growth 2023-2028 (%); 6.5 Acne vulgaris - Market size and forecast 2023-2028; Exhibit 42: Chart on Acne vulgaris - Market size and forecast 2023-2028 ($ billion); Exhibit 43: Data Table on Acne vulgaris - Market size and forecast 2023-2028 ($ billion); Exhibit 44: Chart on Acne vulgaris - Year-over-year growth 2023-2028 (%); Exhibit 45: Data Table on Acne vulgaris - Year-over-year growth 2023-2028 (%); 6.6 Others - Market size and forecast 2023-2028; Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ billion); Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ billion); Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%); 6.7 Market opportunity by Therapy Area; Exhibit 50: Market opportunity by Therapy Area ($ billion); Exhibit 51: Data Table on Market opportunity by Therapy Area ($ billion)
7 Market Segmentation by Route of Administration: 7.1 Market segments; Exhibit 52: Chart on Route of Administration - Market share 2023-2028 (%); Exhibit 53: Data Table on Route of Administration - Market share 2023-2028 (%); 7.2 Comparison by Route of Administration; Exhibit 54: Chart on Comparison by Route of Administration; Exhibit 55: Data Table on Comparison by Route of Administration; 7.3 Injectable - Market size and forecast 2023-2028; Exhibit 56: Chart on Injectable - Market size and forecast 2023-2028 ($ billion); Exhibit 57: Data Table on Injectable - Market size and forecast 2023-2028 ($ billion); Exhibit 58: Chart on Injectable - Year-over-year growth 2023-2028 (%); Exhibit 59: Data Table on Injectable - Year-over-year growth 2023-2028 (%); 7.4 Oral - Market size and forecast 2023-2028; Exhibit 60: Chart on Oral - Market size and forecast 2023-2028 ($ billion); Exhibit 61: Data Table on Oral - Market size and forecast 2023-2028 ($ billion); Exhibit 62: Chart on Oral - Year-over-year growth 2023-2028 (%); Exhibit 63: Data Table on Oral - Year-over-year growth 2023-2028 (%); 7.5 Topical - Market size and forecast 2023-2028; Exhibit 64: Chart on Topical - Market size and forecast 2023-2028 ($ billion); Exhibit 65: Data Table on Topical - Market size and forecast 2023-2028 ($ billion); Exhibit 66: Chart on Topical - Year-over-year growth 2023-2028 (%); Exhibit 67: Data Table on Topical - Year-over-year growth 2023-2028 (%); 7.6 Market opportunity by Route of Administration; Exhibit 68: Market opportunity by Route of Administration ($ billion); Exhibit 69: Data Table on Market opportunity by Route of Administration ($ billion)
8 Customer Landscape: 8.1 Customer landscape overview; Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%); Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%); 9.2 Geographic comparison; Exhibit 73: Chart on Geographic comparison; Exhibit 74: Data Table on Geographic comparison; 9.3 North America - Market size and forecast 2023-2028; Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion); Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion); Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%); 9.4 Europe - Market size and forecast 2023-2028; Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion); Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion); Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%); 9.5 Asia - Market size and forecast 2023-2028; Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion); Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion); Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%); 9.6 Rest of World (ROW) - Market size and forecast 2023-2028; Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); 9.7 US - Market size and forecast 2023-2028; Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion); Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion); Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%); Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%); 9.8 Germany - Market size and forecast 2023-2028; Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion); Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion); Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%); 9.9 UK - Market size and forecast 2023-2028; Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion); Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion); Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%); 9.10 Canada - Market size and forecast 2023-2028; Exhibit 103: Chart on Canada - Market size and forecast 2023-2028 ($ billion); Exhibit 104: Data Table on Canada - Market size and forecast 2023-2028 ($ billion); Exhibit 105: Chart on Canada - Year-over-year growth 2023-2028 (%); Exhibit 106: Data Table on Canada - Year-over-year growth 2023-2028 (%); 9.11 China - Market size and forecast 2023-2028; Exhibit 107: Chart on China - Market size and forecast 2023-2028 ($ billion); Exhibit 108: Data Table on China - Market size and forecast 2023-2028 ($ billion); Exhibit 109: Chart on China - Year-over-year growth 2023-2028 (%); Exhibit 110: Data Table on China - Year-over-year growth 2023-2028 (%); 9.12 Market opportunity By Geographical Landscape; Exhibit 111: Market opportunity By Geographical Landscape ($ billion); Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)
10 Drivers, Challenges, and Trends: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Exhibit 113: Impact of drivers and challenges in 2023 and 2028; 10.4 Market trends
11 Vendor Landscape: 11.1 Overview; 11.2 Vendor landscape; Exhibit 114: Overview on Criticality of inputs and Factors of differentiation; 11.3 Landscape disruption; Exhibit 115: Overview on factors of disruption; 11.4 Industry risks; Exhibit 116: Impact of key risks on business
12 Vendor Analysis: 12.1 Vendors covered; Exhibit 117: Vendors covered; 12.2 Market positioning of vendors; Exhibit 118: Matrix on vendor position and classification; 12.3 AbbVie Inc.; Exhibit 119: AbbVie Inc. - Overview; Exhibit 120: AbbVie Inc. - Product / Service; Exhibit 121: AbbVie Inc. - Key news; Exhibit 122: AbbVie Inc. - Key offerings; 12.4 Amgen Inc.; Exhibit 123: Amgen Inc. - Overview; Exhibit 124: Amgen Inc. - Product / Service; Exhibit 125: Amgen Inc. - Key offerings; 12.5 AstraZeneca Plc; Exhibit 126: AstraZeneca Plc - Overview; Exhibit 127: AstraZeneca Plc - Product / Service; Exhibit 128: AstraZeneca Plc - Key news; Exhibit 129: AstraZeneca Plc - Key offerings; 12.6 Bayer AG; Exhibit 130: Bayer AG - Overview; Exhibit 131: Bayer AG - Business segments; Exhibit 132: Bayer AG - Key news; Exhibit 133: Bayer AG - Key offerings; Exhibit 134: Bayer AG - Segment focus; 12.7 Bristol Myers Squibb Co.; Exhibit 135: Bristol Myers Squibb Co. - Overview; Exhibit 136: Bristol Myers Squibb Co. - Product / Service; Exhibit 137: Bristol Myers Squibb Co. - Key news; Exhibit 138: Bristol Myers Squibb Co. - Key offerings; 12.8 Eli Lilly and Co.; Exhibit 139: Eli Lilly and Co. - Overview; Exhibit 140: Eli Lilly and Co. - Product / Service; Exhibit 141: Eli Lilly and Co. - Key news; Exhibit 142: Eli Lilly and Co. - Key offerings; 12.9 F. Hoffmann La Roche Ltd.; Exhibit 143: F. Hoffmann La Roche Ltd. - Overview; Exhibit 144: F. Hoffmann La Roche Ltd. - Business segments; Exhibit 145: F. Hoffmann La Roche Ltd. - Key news; Exhibit 146: F. Hoffmann La Roche Ltd. - Key offerings; Exhibit 147: F. Hoffmann La Roche Ltd. - Segment focus; 12.10 Galderma SA; Exhibit 148: Galderma SA - Overview; Exhibit 149: Galderma SA - Product / Service; Exhibit 150: Galderma SA - Key news; Exhibit 151: Galderma SA - Key offerings; 12.11 GlaxoSmithKline Plc; Exhibit 152: GlaxoSmithKline Plc - Overview; Exhibit 153: GlaxoSmithKline Plc - Business segments; Exhibit 154: GlaxoSmithKline Plc - Key news; Exhibit 155: GlaxoSmithKline Plc - Key offerings; Exhibit 156: GlaxoSmithKline Plc - Segment focus; 12.12 LEO Pharma AS; Exhibit 157: LEO Pharma AS - Overview; Exhibit 158: LEO Pharma AS - Business segments; Exhibit 159: LEO Pharma AS - Key offerings; Exhibit 160: LEO Pharma AS - Segment focus; 12.13 Merck KGaA; Exhibit 161: Merck KGaA - Overview; Exhibit 162: Merck KGaA - Business segments; Exhibit 163: Merck KGaA - Key news; Exhibit 164: Merck KGaA - Key offerings; Exhibit 165: Merck KGaA - Segment focus; 12.14 Novartis AG; Exhibit 166: Novartis AG - Overview; Exhibit 167: Novartis AG - Business segments; Exhibit 168: Novartis AG - Key offerings; Exhibit 169: Novartis AG - Segment focus; 12.15 Pfizer Inc.; Exhibit 170: Pfizer Inc. - Overview; Exhibit 171: Pfizer Inc. - Product / Service; Exhibit 172: Pfizer Inc. - Key news; Exhibit 173: Pfizer Inc. - Key offerings; 12.16 Sanofi SA; Exhibit 174: Sanofi SA - Overview; Exhibit 175: Sanofi SA - Business segments; Exhibit 176: Sanofi SA - Key news; Exhibit 177: Sanofi SA - Key offerings; Exhibit 178: Sanofi SA - Segment focus; 12.17 Sun Pharmaceutical Industries Ltd.; Exhibit 179: Sun Pharmaceutical Industries Ltd. - Overview; Exhibit 180: Sun Pharmaceutical Industries Ltd. - Product / Service; Exhibit 181: Sun Pharmaceutical Industries Ltd. - Key offerings
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Exhibit 182: Inclusions checklist; Exhibit 183: Exclusions checklist; 13.3 Currency conversion rates for US$; Exhibit 184: Currency conversion rates for US$; 13.4 Research methodology; Exhibit 185: Research methodology; Exhibit 186: Validation techniques employed for market sizing; Exhibit 187: Information sources; 13.5 List of abbreviations; Exhibit 188: List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market By Geographical Landscape; Exhibits5: Executive Summary - Chart on Market Segmentation by Therapy Area; Exhibits6: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Vendor Market Positioning; Exhibits10: Parent market; Exhibits11: Market Characteristics; Exhibits12: Offerings of vendors included in the market definition; Exhibits13: Market segments; Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ billion); Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ billion); Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%); Exhibits18: Historic Market Size - Data Table on global non-cancerous skin diseases therapeutics market 2018 - 2022 ($ billion); Exhibits19: Historic Market Size - Therapy area Segment 2018 - 2022 ($ billion); Exhibits20: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ billion); Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion); Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ billion); Exhibits23: Five forces analysis - Comparison between 2023 and 2028; Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits29: Chart on Market condition - Five forces 2023 and 2028; Exhibits30: Chart on Therapy Area - Market share 2023-2028 (%); Exhibits31: Data Table on Therapy Area - Market share 2023-2028 (%); Exhibits32: Chart on Comparison by Therapy Area; Exhibits33: Data Table on Comparison by Therapy Area; Exhibits34: Chart on Psoriasis - Market size and forecast 2023-2028 ($ billion); Exhibits35: Data Table on Psoriasis - Market size and forecast 2023-2028 ($ billion); Exhibits36: Chart on Psoriasis - Year-over-year growth 2023-2028 (%); Exhibits37: Data Table on Psoriasis - Year-over-year growth 2023-2028 (%); Exhibits38: Chart on Eczema - Market size and forecast 2023-2028 ($ billion); Exhibits39: Data Table on Eczema - Market size and forecast 2023-2028 ($ billion); Exhibits40: Chart on Eczema - Year-over-year growth 2023-2028 (%); Exhibits41: Data Table on Eczema - Year-over-year growth 2023-2028 (%); Exhibits42: Chart on Acne vulgaris - Market size and forecast 2023-2028 ($ billion); Exhibits43: Data Table on Acne vulgaris - Market size and forecast 2023-2028 ($ billion); Exhibits44: Chart on Acne vulgaris - Year-over-year growth 2023-2028 (%); Exhibits45: Data Table on Acne vulgaris - Year-over-year growth 2023-2028 (%); Exhibits46: Chart on Others - Market size and forecast 2023-2028 ($ billion); Exhibits47: Data Table on Others - Market size and forecast 2023-2028 ($ billion); Exhibits48: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibits49: Data Table on Others - Year-over-year growth 2023-2028 (%); Exhibits50: Market opportunity by Therapy Area ($ billion); Exhibits51: Data Table on Market opportunity by Therapy Area ($ billion); Exhibits52: Chart on Route of Administration - Market share 2023-2028 (%); Exhibits53: Data Table on Route of Administration - Market share 2023-2028 (%); Exhibits54: Chart on Comparison by Route of Administration; Exhibits55: Data Table on Comparison by Route of Administration; Exhibits56: Chart on Injectable - Market size and forecast 2023-2028 ($ billion); Exhibits57: Data Table on Injectable - Market size and forecast 2023-2028 ($ billion); Exhibits58: Chart on Injectable - Year-over-year growth 2023-2028 (%); Exhibits59: Data Table on Injectable - Year-over-year growth 2023-2028 (%); Exhibits60: Chart on Oral - Market size and forecast 2023-2028 ($ billion); Exhibits61: Data Table on Oral - Market size and forecast 2023-2028 ($ billion); Exhibits62: Chart on Oral - Year-over-year growth 2023-2028 (%); Exhibits63: Data Table on Oral - Year-over-year growth 2023-2028 (%); Exhibits64: Chart on Topical - Market size and forecast 2023-2028 ($ billion); Exhibits65: Data Table on Topical - Market size and forecast 2023-2028 ($ billion); Exhibits66: Chart on Topical - Year-over-year growth 2023-2028 (%); Exhibits67: Data Table on Topical - Year-over-year growth 2023-2028 (%); Exhibits68: Market opportunity by Route of Administration ($ billion); Exhibits69: Data Table on Market opportunity by Route of Administration ($ billion); Exhibits70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits71: Chart on Market share By Geographical Landscape 2023-2028 (%); Exhibits72: Data Table on Market share By Geographical Landscape 2023-2028 (%); Exhibits73: Chart on Geographic comparison; Exhibits74: Data Table on Geographic comparison; Exhibits75: Chart on North America - Market size and forecast 2023-2028 ($ billion); Exhibits76: Data Table on North America - Market size and forecast 2023-2028 ($ billion); Exhibits77: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibits78: Data Table on North America - Year-over-year growth 2023-2028 (%); Exhibits79: Chart on Europe - Market size and forecast 2023-2028 ($ billion); Exhibits80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion); Exhibits81: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibits82: Data Table on Europe - Year-over-year growth 2023-2028 (%); Exhibits83: Chart on Asia - Market size and forecast 2023-2028 ($ billion); Exhibits84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion); Exhibits85: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibits86: Data Table on Asia - Year-over-year growth 2023-2028 (%); Exhibits87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibits88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibits89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits91: Chart on US - Market size and forecast 2023-2028 ($ billion); Exhibits92: Data Table on US - Market size and forecast 2023-2028 ($ billion); Exhibits93: Chart on US - Year-over-year growth 2023-2028 (%); Exhibits94: Data Table on US - Year-over-year growth 2023-2028 (%); Exhibits95: Chart on Germany - Market size and forecast 2023-2028 ($ billion); Exhibits96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion); Exhibits97: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibits98: Data Table on Germany - Year-over-year growth 2023-2028 (%); Exhibits99: Chart on UK - Market size and forecast 2023-2028 ($ billion); Exhibits100: Data Table on UK - Market size and forecast 2023-2028 ($ billion); Exhibits101: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibits102: Data Table on UK - Year-over-year growth 2023-2028 (%); Exhibits103: Chart on Canada - Market size and forecast 2023-2028 ($ billion); Exhibits104: Data Table on Canada - Market size and forecast 2023-2028 ($ billion); Exhibits105: Chart on Canada - Year-over-year growth 2023-2028 (%); Exhibits106: Data Table on Canada - Year-over-year growth 2023-2028 (%); Exhibits107: Chart on China - Market size and forecast 2023-2028 ($ billion); Exhibits108: Data Table on China - Market size and forecast 2023-2028 ($ billion); Exhibits109: Chart on China - Year-over-year growth 2023-2028 (%); Exhibits110: Data Table on China - Year-over-year growth 2023-2028 (%); Exhibits111: Market opportunity By Geographical Landscape ($ billion); Exhibits112: Data Tables on Market opportunity By Geographical Landscape ($ billion); Exhibits113: Impact of drivers and challenges in 2023 and 2028; Exhibits114: Overview on Criticality of inputs and Factors of differentiation; Exhibits115: Overview on factors of disruption; Exhibits116: Impact of key risks on business; Exhibits117: Vendors covered; Exhibits118: Matrix on vendor position and classification; Exhibits119: AbbVie Inc. - Overview; Exhibits120: AbbVie Inc. - Product / Service; Exhibits121: AbbVie Inc. - Key news; Exhibits122: AbbVie Inc. - Key offerings; Exhibits123: Amgen Inc. - Overview; Exhibits124: Amgen Inc. - Product / Service; Exhibits125: Amgen Inc. - Key offerings; Exhibits126: AstraZeneca Plc - Overview; Exhibits127: AstraZeneca Plc - Product / Service; Exhibits128: AstraZeneca Plc - Key news; Exhibits129: AstraZeneca Plc - Key offerings; Exhibits130: Bayer AG - Overview; Exhibits131: Bayer AG - Business segments; Exhibits132: Bayer AG - Key news; Exhibits133: Bayer AG - Key offerings; Exhibits134: Bayer AG - Segment focus; Exhibits135: Bristol Myers Squibb Co. - Overview; Exhibits136: Bristol Myers Squibb Co. - Product / Service; Exhibits137: Bristol Myers Squibb Co. - Key news; Exhibits138: Bristol Myers Squibb Co. - Key offerings; Exhibits139: Eli Lilly and Co. - Overview; Exhibits140: Eli Lilly and Co. - Product / Service; Exhibits141: Eli Lilly and Co. - Key news; Exhibits142: Eli Lilly and Co. - Key offerings; Exhibits143: F. Hoffmann La Roche Ltd. - Overview; Exhibits144: F. Hoffmann La Roche Ltd. - Business segments; Exhibits145: F. Hoffmann La Roche Ltd. - Key news; Exhibits146: F. Hoffmann La Roche Ltd. - Key offerings; Exhibits147: F. Hoffmann La Roche Ltd. - Segment focus; Exhibits148: Galderma SA - Overview; Exhibits149: Galderma SA - Product / Service; Exhibits150: Galderma SA - Key news; Exhibits151: Galderma SA - Key offerings; Exhibits152: GlaxoSmithKline Plc - Overview; Exhibits153: GlaxoSmithKline Plc - Business segments; Exhibits154: GlaxoSmithKline Plc - Key news; Exhibits155: GlaxoSmithKline Plc - Key offerings; Exhibits156: GlaxoSmithKline Plc - Segment focus; Exhibits157: LEO Pharma AS - Overview; Exhibits158: LEO Pharma AS - Business segments; Exhibits159: LEO Pharma AS - Key offerings; Exhibits160: LEO Pharma AS - Segment focus; Exhibits161: Merck KGaA - Overview; Exhibits162: Merck KGaA - Business segments; Exhibits163: Merck KGaA - Key news; Exhibits164: Merck KGaA - Key offerings; Exhibits165: Merck KGaA - Segment focus; Exhibits166: Novartis AG - Overview; Exhibits167: Novartis AG - Business segments; Exhibits168: Novartis AG - Key offerings; Exhibits169: Novartis AG - Segment focus; Exhibits170: Pfizer Inc. - Overview; Exhibits171: Pfizer Inc. - Product / Service; Exhibits172: Pfizer Inc. - Key news; Exhibits173: Pfizer Inc. - Key offerings; Exhibits174: Sanofi SA - Overview; Exhibits175: Sanofi SA - Business segments; Exhibits176: Sanofi SA - Key news; Exhibits177: Sanofi SA - Key offerings; Exhibits178: Sanofi SA - Segment focus; Exhibits179: Sun Pharmaceutical Industries Ltd. - Overview; Exhibits180: Sun Pharmaceutical Industries Ltd. - Product / Service; Exhibits181: Sun Pharmaceutical Industries Ltd. - Key offerings; Exhibits182: Inclusions checklist; Exhibits183: Exclusions checklist; Exhibits184: Currency conversion rates for US$; Exhibits185: Research methodology; Exhibits186: Validation techniques employed for market sizing; Exhibits187: Information sources; Exhibits188: List of abbreviations